Clinical Trial Update: Topical Rapamycin to Erase Angiofibromas in TSC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating topical rapamycin to reduce facial angiofibromas in tuberous sclerosis complex completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angiofibromas
• Tuberous Sclerosis

Drugs mentioned

• Rapamycin (sirolimus)

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Angiofibromas, Tuberous Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2020-10-26